Zebrafish Help Canadian Researchers Provide Answers to Cause of ALS

MARKHAM, ONTARIO  June 4, 2013 — Canadian researcher Edor Kabashi of the Université de Montréal has developed the first animal model to study the function of a gene responsible for the highest percentage of ALS, commonly known as Lou Gehrig’s disease. Results to date shed light on the cause of the devastating disease.
“Our results indicate that [...]

Categories: ALS News, Research News, Treatments  |  Tags: ALS, ALS community, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, C9ORF72, C9ORF72 gene, Edor Kabash, Lindee David ALS Canada, Lou Gehrig's disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Université de Montréal, zebrafish ALS  |  No comments

ALS Breakthrough Underscores Importance of Collaboration to Brain Research

As the result of a major breakthrough by researchers at Northwestern University’s School of Medicine, researchers studying amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s Disease, are now one step closer to unlocking the nature of ALS. The recent discovery, which for the first time identified a gene both in motor neurons in the brain and spinal cord affected by ALS, offers a glimpse of hope to those who currently suffer from the deadly disease which rapidly breaks down their bodies while leaving mental capacity intact.

Categories: 501(c)(3) Non-Profit, ALS Community News, ALS News, Research News  |  Tags: ALS, ALS community, ALS diagnosis, ALS diagnostics, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Les Turner ALS Foundation, Lou Gehrig's disease, National Institutes of Health (NIH), Northwestern University's School of Medicine, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Terre Constantine, Wenske Foundation  |  No comments

RASCALS Scholarship Deadline July 1st, 2013

The RASCALS Foundation would like to remind all ALS Families that there is still time to apply for the Higher Education Scholarship.
The Foundation is accepting applications and the deadline is fast approaching. All entries must be postmarked by July 1, 2013!
Click on the Guidelines tab for more information and contact us through this website [...]

Categories: 501(c)(3) Non-Profit, ALS Families, RASCALS Foundation News  |  Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS community, ALS scholarship funding, ALS Scholarships, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig's disease, PALS, RASCALS Foundation, RASCALS Foundation Higher Education Scholarship 2013, RASCALS Higher Education Scholarships, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Walgreens  |  No comments

Melissa Marr Joins RASCALS Board of Directors

This spirit of volunteerism also extends to our leadership. We have been fortunate to have some very bright and energetic people step forward to help plan how we might best serve the ALS community. With that in mind, we proudly announce that Melissa Marr has accepted the position of Marketing Director on the RASCALS Foundation Board of Directors.

Categories: 501(c)(3) Non-Profit, ALS Community News, ALS News, RASCALS Foundation News  |  Tags: 501(c)(3) ALS charity, ALS, ALS charity, ALS community, ALS research funding, amyotrophic lateral sclerosis, Bob Stehlin, InsideSTL.com, KFNS Sports Radio, Lou Gehrig's disease, Melissa Marr, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Southeast Missouri State University, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis  |  No comments

Breaking News: ALS Awareness Month Has Changed — to ALS Action Month

We are a 100% all-volunteer 501(c)(3) non-profit charity. No one takes a paycheck here and there are no administrative costs. That means 100% of all funds raised by the R.A.S.C.A.L.S. Foundation go directly to fighting ALS.

The money goes to fund promising treatment research and development. It helps with ALS family assistance, such as our annual Higher Education Scholarship program.

Categories: 501(c)(3) Non-Profit, ALS Community News, ALS Families, ALS News, Caretakers  |  Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS charity, ALS community, ALS cure, ALS diagnosis, ALS donations, ALS funding, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig's disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis  |  No comments

Pitt Findings on Lou Gehrig’s Disease May Hold Hope

By Kaitlynn Riely for the Pittsburgh Post-Gazette, April 26, 2013 •
A person diagnosed this year with amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig’s disease, will receive basically the same prognosis as the New York Yankee did — an average life expectancy of two to five years.
More than 70 years after Gehrig’s death, [...]

Categories: ALS News, Research News, Technology, Treatments  |  Tags: ALS, ALS community, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bedford VA Medical System Boston, Bob Stehlin, Department of Defense, Department of Neurological Surgery Pitt School of Medicine, Harvard Medical School, Lou Gehrig's disease, Melatonin injections ALS, melatonin receptor 1 ALS, MT1 ALS, Muscular Dystrophy Association, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Ohio State University, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Robert Friedlander, St. Joseph's Hospital and Medical Center Phoenix, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, University of Pittsburgh School of Medicine, University of Texas Medical School at Houston, VA Pittsburgh Health Care System, Weifang Medical University  |  No comments

Pitt Team Finds Melatonin Delays ALS Symptom Onset and Death in Mice

Hoping to stop neuron death in ALS just as they did in Huntington’s, the research team treated mice bred to have an ALS-like disease with injections of melatonin or with a placebo. Compared to untreated animals, the melatonin group developed symptoms later, survived longer, and had less degeneration of motor neurons in the spinal cord.

Categories: ALS News, Research News, Technology, Treatments  |  Tags: ALS, ALS community, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bedford VA Medical System Boston, Bob Stehlin, Department of Defense, Department of Neurological Surgery Pitt School of Medicine, Harvard Medical School, Lou Gehrig's disease, Melatonin injections ALS, melatonin receptor 1 ALS, MT1 ALS, Muscular Dystrophy Association, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Ohio State University, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Robert Friedlander, St. Joseph's Hospital and Medical Center Phoenix, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, University of Pittsburgh School of Medicine, University of Texas Medical School at Houston, VA Pittsburgh Health Care System, Weifang Medical University  |  No comments

Neuralstem ALS Trial Data Presented at the American Association of Neurological Surgeons Annual Meeting

“That our cells and method of delivery are safe in ALS patients bodes very well for expanding to other indications. We expect to commence our FDA-approved Phase I trial in chronic spinal cord injury later this year using the same methodology. We want to thank the surgeons at Emory, who developed these techniques, as well as the patients and their families who have taken part in the trial.”

Categories: ALS Community News, ALS Families, ALS News, Clinical Trials, Research News, Treatments  |  Tags: ALS, ALS Awareness Month, ALS cell therapy, ALS clinical trial, ALS community, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Intraspinal Stem Cell Transplantation in ALS, Karl Johe, Lou Gehrig's disease, Neuralstem Incorporated, NSI-566 Phase I trial ALS, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis  |  No comments

110% Gratitude to All Our Volunteers

April marks National Volunteer Month. This observance holds very special meaning for all of us here at the Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.). That’s because we are a 100% all-volunteer 501(c)(3) non-profit charity. There are no administrative costs.
That means no salaries, payments, or perks for anyone. Out-of-pocket expenses truly means out of our [...]

Categories: 501(c)(3) Non-Profit, ALS Community News, ALS Families, ALS News, RASCALS Foundation News, Treatments  |  Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS community, ALS cure, ALS diagnosis, ALS diagnostics, ALS donations, ALS funding, ALS medical care, ALS research, ALS research funding, ALS treatments, ALS volunteers, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig's disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis  |  No comments

NEALS SOD1 Research is First Antisense Oligonucleotide Trial for a Central Nervous System Disorder

Antisense Oligonucleotides May be Feasible ALS Therapeutic Strategy

BOSTON, Massachusetts, March 29, 2013 — Published online today in Lancet Neurology, an SOD1-related familial ALS trial under the direction of NEALS researchers Timothy Miller, MD, PhD (Washington University School of Medicine) and Merit Cudkowicz (Massachusetts General Hospital) indicates that antisense oligonucleotide delivery to the central nervous system may [...]

Categories: ALS Community News, ALS News, Clinical Trials, Research News, Treatments  |  Tags: ALS, ALS community, ALS treatments, amyotrophic lateral sclerosis, antisense oligonucleotide, Bob Stehlin, cerebrospinal fluid (CSF) ALS, ISIS 333611, Isis Pharmaceuticals, Johns Hopkins University, Lou Gehrig's disease, Massachusetts General Hospital, Merit Cudkowicz, Methodist Neurological Institute, MGH Neurological Clinical Research Institute (NCRI), Northeast ALS Consortium (NEALS), PALS, RASCALS Foundation, RNA ALS, Robert A. Stehlin Campaign for ALS, SOD-1, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Timothy Miller, Washington University in St. Louis, Washington University School of Medicine  |  No comments